HRP20191805T1 - Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća - Google Patents

Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća Download PDF

Info

Publication number
HRP20191805T1
HRP20191805T1 HRP20191805TT HRP20191805T HRP20191805T1 HR P20191805 T1 HRP20191805 T1 HR P20191805T1 HR P20191805T T HRP20191805T T HR P20191805TT HR P20191805 T HRP20191805 T HR P20191805T HR P20191805 T1 HRP20191805 T1 HR P20191805T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
patient
use according
amikacin
period
Prior art date
Application number
HRP20191805TT
Other languages
English (en)
Croatian (hr)
Inventor
Gina EAGLE
Renu Gupta
Original Assignee
Insmed Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Incorporated filed Critical Insmed Incorporated
Publication of HRP20191805T1 publication Critical patent/HRP20191805T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HRP20191805TT 2014-05-15 2015-05-15 Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća HRP20191805T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461993439P 2014-05-15 2014-05-15
US201462042126P 2014-08-26 2014-08-26
US201462048068P 2014-09-09 2014-09-09
US201462056296P 2014-09-26 2014-09-26
EP15791964.8A EP3142643B1 (en) 2014-05-15 2015-05-15 Methods for treating pulmonary non-tuberculous mycobacterial infections
PCT/US2015/031079 WO2015175939A1 (en) 2014-05-15 2015-05-15 Methods for treating pulmonary non-tuberculous mycobacterial infections

Publications (1)

Publication Number Publication Date
HRP20191805T1 true HRP20191805T1 (hr) 2019-12-27

Family

ID=54480776

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191805TT HRP20191805T1 (hr) 2014-05-15 2015-05-15 Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća

Country Status (23)

Country Link
US (16) US9895385B2 (cg-RX-API-DMAC7.html)
EP (5) EP3142643B1 (cg-RX-API-DMAC7.html)
JP (5) JP6646653B2 (cg-RX-API-DMAC7.html)
KR (4) KR20240018675A (cg-RX-API-DMAC7.html)
CN (1) CN106535877A (cg-RX-API-DMAC7.html)
AU (2) AU2015258947B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016026699B1 (cg-RX-API-DMAC7.html)
CA (1) CA2949078C (cg-RX-API-DMAC7.html)
CY (2) CY1122129T1 (cg-RX-API-DMAC7.html)
DK (2) DK3142643T3 (cg-RX-API-DMAC7.html)
ES (4) ES2926985T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191805T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051440T2 (cg-RX-API-DMAC7.html)
LT (2) LT3466432T (cg-RX-API-DMAC7.html)
ME (1) ME03536B (cg-RX-API-DMAC7.html)
MX (2) MX376012B (cg-RX-API-DMAC7.html)
NZ (1) NZ726256A (cg-RX-API-DMAC7.html)
PL (2) PL3142643T3 (cg-RX-API-DMAC7.html)
PT (2) PT3466432T (cg-RX-API-DMAC7.html)
RS (1) RS60827B1 (cg-RX-API-DMAC7.html)
SI (2) SI3142643T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000516T1 (cg-RX-API-DMAC7.html)
WO (1) WO2015175939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1962805T3 (en) 2005-12-08 2016-09-26 Insmed Inc Lipid-based compositions of the anti-infective agents for the treatment of lung infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
NO2699580T3 (cg-RX-API-DMAC7.html) 2014-01-24 2018-02-24
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
KR20250107292A (ko) * 2016-07-29 2025-07-11 인스메드 인코포레이티드 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
WO2018186998A1 (en) * 2017-04-05 2018-10-11 Aradigm Corporation Liposomal anti-infective formulations to inhibit non-tuberculous mycobacteria (ntm) microaggregate formation and establishment of ntm biofilm
JP7545893B2 (ja) * 2017-10-16 2024-09-05 ドラッグレキュア エーピーエス 難治性非結核性マイコバクテリア感染症の治療のためのｇｍ－ｃｓｆ
CN108310393A (zh) * 2018-02-12 2018-07-24 丹诺医药(苏州）有限公司 一种利福霉素-喹嗪酮偶联分子的应用
KR102738945B1 (ko) 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
US10736847B2 (en) * 2018-07-03 2020-08-11 Becton, Dickinson And Company Inverting device for liposome preparation by centrifugation
AU2019306532A1 (en) 2018-07-17 2021-03-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
US20220081470A1 (en) * 2019-01-05 2022-03-17 Foundation For Neglected Disease Research Thiazolyl peptides for the treatment nontuberculous mycobacterial infections
CN113271930A (zh) * 2019-01-09 2021-08-17 詹森药业有限公司 治疗非结核分枝杆菌疾病的组合
CN121221570A (zh) * 2019-11-06 2025-12-30 曼金德公司 氯法齐明的组合物，含它们的组合，它们的制备方法，含它们的用途和治疗方法
KR102275997B1 (ko) * 2019-11-07 2021-07-13 연세대학교 산학협력단 숙주지향치료를 위한 조성물
US11808135B2 (en) 2020-01-16 2023-11-07 Halliburton Energy Services, Inc. Systems and methods to perform a downhole inspection in real-time
KR20220022877A (ko) * 2020-08-19 2022-02-28 주식회사 미토이뮨테라퓨틱스 Ｍabc-R 감염에 의한 병적 염증 치료제로서의 미토콘드리아 표적 항산화제
JP2023538853A (ja) * 2020-08-31 2023-09-12 インスメッド インコーポレイテッド 新たに診断されたマイコバクテリウム・アビウム・コンプレックス肺感染症の処置方法
JP2024511419A (ja) * 2021-03-24 2024-03-13 インスメッド インコーポレイテッド 非結核性抗酸菌肺疾患を治療するための併用療法
WO2022261459A1 (en) * 2021-06-11 2022-12-15 Colorado State University Research Foundation Compositions and methods for treating non-tuberculous mycobacterial infections
KR102596057B1 (ko) * 2021-11-05 2023-11-01 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염질환 진단용 지질대사체 마커
KR102613631B1 (ko) * 2021-11-05 2023-12-15 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염증의 중증도 예측용 대사체 마커
WO2023080663A1 (ko) * 2021-11-05 2023-05-11 연세대학교 산학협력단 마이코박테리움 아비움 복합체 감염질환 진단 또는 중증도 예측용 대사체 마커
KR102615869B1 (ko) * 2021-11-05 2023-12-21 연세대학교 산학협력단 마이코박테리움 아비움 복합체 폐질환 환자의 정보에 따른 치료 반응 예측용 지질대사체 마커
IL313429A (en) * 2021-12-07 2024-08-01 An2 Therapeutics Inc conjunctions
CN120584108A (zh) 2023-01-06 2025-09-02 英斯梅德股份有限公司 新型可逆dpp1抑制剂及其用途
KR20250047185A (ko) 2023-09-27 2025-04-03 주식회사 엘지에너지솔루션 전해액 제거장치

Family Cites Families (367)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3006698A (en) 1959-11-25 1961-10-31 Gen Motors Corp Bearing assembly
US3061303A (en) 1961-02-21 1962-10-30 Didde Glaser Inc Self-centering parallel guide assembly
US3091572A (en) 1962-07-16 1963-05-28 Schering Corp Gentamycin and method of production
US3136704A (en) 1962-12-05 1964-06-09 Schering Corp Manufacture of gentamycin
US3852557A (en) 1973-07-12 1974-12-03 Cutler Hammer Inc Electric switch with pivoting and wiping movable contractor
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
HU184141B (en) 1979-12-27 1984-07-30 Human Oltoanyagtermelo Adjuvant particles compositions containing said particles and biologically active substances adsorbed thereon and a process for the preparation thereof
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
ATE18353T1 (de) 1981-07-02 1986-03-15 Hoffmann La Roche Verfahren zur herstellung von liposomenloesungen.
US4547490A (en) 1981-12-31 1985-10-15 Neomed, Inc. Synthetic whole blood and a method of making the same
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4684625A (en) 1982-07-08 1987-08-04 Syntex (U.S.A.) Inc. Method for enhancing the anti-infective activity of muramyldipeptide derivatives
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5030453A (en) 1983-03-24 1991-07-09 The Liposome Company, Inc. Stable plurilamellar vesicles
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US5059591B1 (en) 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
CA1237670A (en) 1983-05-26 1988-06-07 Andrew S. Janoff Drug preparations of reduced toxicity
US4606939A (en) 1983-06-22 1986-08-19 The Ohio State University Research Foundation Small particle formation
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
EP0153955A1 (en) 1983-09-06 1985-09-11 Health Research, Inc. Liposome delivery method for decreasing the toxicity of an antitumor drug
US4721612A (en) 1984-04-12 1988-01-26 The Liposome Company, Inc. Steroidal liposomes
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4794000A (en) 1987-01-08 1988-12-27 Synthetic Blood Corporation Coacervate-based oral delivery system for medically useful compositions
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
SE8403905D0 (sv) 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
EP0223831B1 (en) 1985-05-22 1992-07-15 Liposome Technology, Inc. Liposome inhalation method and system
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
CA1314481C (en) 1986-12-23 1993-03-16 Marcel B. Bally Liposomal preparation and antibiotic
JP2579625B2 (ja) 1985-07-05 1997-02-05 ザ リポソ−ム カンパニ−，インコ−ポレイテツド 改良された取り込み効率を有するマルチラメラリポソ−ム
JPH0665648B2 (ja) 1985-09-25 1994-08-24 塩野義製薬株式会社 白金系抗癌物質の安定な凍結真空乾燥製剤
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4861580A (en) 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
US5041581A (en) 1985-10-18 1991-08-20 The University Of Texas System Board Of Regents Hydrophobic cis-platinum complexes efficiently incorporated into liposomes
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US4833134A (en) 1986-08-19 1989-05-23 Takeda Chemical Industries, Ltd. Cephem compounds
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4933121A (en) 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
US5320906A (en) 1986-12-15 1994-06-14 Vestar, Inc. Delivery vehicles with amphiphile-associated active ingredient
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5616334A (en) 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
DE3852037T2 (de) 1987-07-29 1995-03-23 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
US4857311A (en) 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
MX9203504A (es) 1988-04-20 1992-07-01 Liposome Co Inc Complejo agente: lipido activo de alta proporcion.
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
BE1001869A3 (fr) 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
US4952405A (en) 1988-10-20 1990-08-28 Liposome Technology, Inc. Method of treating M. avium infection
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5843473A (en) 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
WO1991009616A1 (en) 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5820848A (en) 1990-01-12 1998-10-13 The Liposome Company, Inc. Methods of preparing interdigitation-fusion liposomes and gels which encapsulate a bioactive agent
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991016882A1 (en) 1990-05-08 1991-11-14 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US6623671B2 (en) 1990-10-05 2003-09-23 Royden M. Coe Liposome extrusion process
US5614216A (en) 1990-10-17 1997-03-25 The Liposome Company, Inc. Synthetic lung surfactant
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
DK0525132T3 (da) 1991-02-14 1996-02-05 Baxter Int Binding af genkendende stoffer til liposomer
US5228346A (en) 1991-04-08 1993-07-20 Marathon Oil Company Method of determining gas flow volume
US6629646B1 (en) 1991-04-24 2003-10-07 Aerogen, Inc. Droplet ejector with oscillating tapered aperture
DE59108798D1 (de) 1991-11-07 1997-08-28 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
US5770563A (en) 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
EP0625207A1 (en) 1991-12-17 1994-11-23 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6890555B1 (en) 1992-02-05 2005-05-10 Qlt, Inc. Liposome compositions of porphyrin photosensitizers
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5871710A (en) 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
WO1994012155A1 (en) 1992-12-02 1994-06-09 Vestar, Inc. Antibiotic formulation and process
US5958449A (en) 1992-12-02 1999-09-28 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for bacterial infections
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
ZA938381B (en) 1993-03-22 1994-06-13 Inland Steel Co Apparatus and method for magnetically confining molten metal using concentrating fins
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
EP0692961A1 (en) 1993-04-02 1996-01-24 The Liposome Company, Inc. Method of producing liposomes
US5759571A (en) 1993-05-11 1998-06-02 Nexstar Pharmaceuticals, Inc. Antibiotic formulation and use for drug resistant infections
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JPH06345663A (ja) 1993-06-08 1994-12-20 Sumitomo Pharmaceut Co Ltd バンコマイシン含有リポソーム製剤
ATE199640T1 (de) 1993-07-08 2001-03-15 Liposome Co Inc Verfahren zum kontrollieren der liposomengrösse
CA2101241C (en) 1993-07-23 1998-12-22 Jonathan P. Wong Liposome-encapsulated ciprofloxacin
DE69409361T2 (de) 1993-11-05 1998-11-12 Amgen Inc Herstellung von liposomen und verfahren zur substanzverkapselung
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
WO1995016464A1 (en) 1993-12-14 1995-06-22 Johns Hopkins University School Of Medicine Controlled release of pharmaceutically active substances for immunotherapy
ATE168289T1 (de) 1993-12-17 1998-08-15 Pari Gmbh Zerstäuberdüse
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
US5610198A (en) 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
ATE205098T1 (de) 1994-05-19 2001-09-15 Pari Gmbh Vorrichtung zur trocknung und pufferung von aerosolen
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
AR002009A1 (es) 1994-12-22 1998-01-07 Astra Ab Composicion farmaceutica, procedimiento para la manufactura de un polvo de proliposoma como el utilizado en dicha composicion, procedimiento para lamanufactura de dicha composicion, uso de dicha composicion farmaceutica en la manufactura de un medicamento y dispositivo inhalador de polvo seco.
US5662929A (en) 1994-12-23 1997-09-02 Universite De Montreal Therapeutic liposomal formulation
US5883074A (en) 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
DE69632859T2 (de) 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US5855610A (en) 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
JPH11508231A (ja) 1995-05-26 1999-07-21 ソマティックス セラピー コーポレイション 安定な脂質／核酸複合体を含む送達ビヒクル
DE69620136T2 (de) 1995-06-06 2002-08-01 Bayer Ag Antibakterielle präparate für die ohren ohne irritierende, sensibilisierende und ototoxische wirkungen
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CA2224253A1 (en) 1995-06-09 1996-12-27 Martin J. Macphee Chitin hydrogels, methods of their production and use
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
NZ322686A (en) 1995-10-19 2000-01-28 Univ Washington Discrete-length polyethene glycols
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
GB9602969D0 (en) 1996-02-13 1996-04-10 The Technology Partnership Plc Liquid supply apparatus
US5840702A (en) 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
CA2250219C (en) 1996-03-28 2008-10-07 Hayat Onyuksel Materials and methods for making improved liposome compositions
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US6132765A (en) 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
CA2174803C (en) 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
JP2000510460A (ja) 1996-04-26 2000-08-15 マゲイニン・ファーマシューティカルズ・インコーポレーテッド スクアラミンを他の抗癌剤と併用する上皮性悪性腫瘍の治療
GB9609779D0 (en) 1996-05-10 1996-07-17 Univ Bruxelles Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
EP0929293B1 (en) 1996-08-23 2003-10-22 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
CA2628857C (en) 1996-12-30 2011-09-13 Batelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE19713636A1 (de) 1997-04-02 1998-10-08 Pari Gmbh Atemzugsimulator
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US5957339A (en) 1997-06-23 1999-09-28 Keystone Manufacturing Co., Inc. Water filtration system
JP4142149B2 (ja) 1997-07-10 2008-08-27 明治製菓株式会社 バンコマイシンの凍結乾燥製剤
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
CA2215716C (en) 1997-09-17 1999-12-07 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Aerosol delivery of liposome-encapsulated fluoroquinolone
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
CA2308201C (en) 1997-10-22 2010-09-28 Jens Ponikau Use of anti-fungal agents for the treatment of fungus-induced mucositis
ATE554748T1 (de) 1997-11-14 2012-05-15 Pacira Pharmaceuticals Inc Herstellung von multivesikulären liposomen
US6051251A (en) 1997-11-20 2000-04-18 Alza Corporation Liposome loading method using a boronic acid compound
WO1999030686A1 (en) 1997-12-12 1999-06-24 Inex Pharmaceuticals Corp. Cationic drugs encapsulated in anionic liposomes
GB9827370D0 (en) 1998-01-16 1999-02-03 Pari Gmbh Mouthpiece for inhalation therapy units
US6468532B1 (en) 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
HU226710B1 (en) 1998-05-27 2009-07-28 Euro Celtique Sa Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the upper respiratory tract and/or the ear
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
ATE355827T1 (de) 1998-08-12 2007-03-15 Yissum Res Dev Co Mittels ammoniumsulfatgradient hergestellte liposomale therapeutische zusammensetzungen
DE19846382C1 (de) 1998-10-08 2000-07-06 Pari Gmbh Zählwerk und seine Verwendung in Inhalatoren, Verneblern oder ähnlichen Dosieraerosolvorrichtungen
WO2000027359A1 (en) 1998-11-12 2000-05-18 Pilkiewicz Frank G An inhalation system
DE69938875D1 (cg-RX-API-DMAC7.html) 1998-11-13 2008-07-17 William A Heriot
US6855296B1 (en) 1998-11-13 2005-02-15 Optime Therapeutics, Inc. Method and apparatus for liposome production
HK1043732A1 (zh) * 1998-12-17 2002-09-27 Chiron Corporation 利用烟雾状抗生素治疗严重慢性支气管炎(支气管扩张)的方法
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
CN1198589C (zh) 1999-02-08 2005-04-27 阿尔扎有限公司 控制脂质体大小的方法
WO2000059528A1 (en) 1999-04-02 2000-10-12 The Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
WO2000074634A2 (en) 1999-06-03 2000-12-14 Au Jessie L S Methods and compositions for modulating cell proliferation and cell death
CA2376849C (en) 1999-06-24 2008-10-14 Kyowa Hakko Kogyo Co., Ltd. Method of inhibiting leakage of drug encapsulated in liposomes
AU769357B2 (en) 1999-07-15 2004-01-22 University Of British Columbia, The Methods for preparation of lipid-encapsulated therapeutic agents
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
JP4198850B2 (ja) 1999-11-29 2008-12-17 オムロンヘルスケア株式会社 液体噴霧装置
AU777338B2 (en) 1999-12-04 2004-10-14 Research Development Foundation Carbon dioxide enhancement of inhalation therapy
DE10004465A1 (de) 2000-02-02 2001-08-16 Pari Gmbh Inhalationsvernebler
DE60123583T2 (de) 2000-02-04 2007-08-09 Lipoxen Technologies Ltd. Dehydratisierungs-/rehydratisierungsverfahren zur herstellung von liposome
US6761877B2 (en) 2000-02-18 2004-07-13 Biocrystal, Ltd. Functionalized encapsulated fluorescent nanocrystals
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US7600511B2 (en) 2001-11-01 2009-10-13 Novartis Pharma Ag Apparatus and methods for delivery of medicament to a respiratory system
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
MXPA02010884A (es) 2000-05-05 2003-03-27 Aerogen Ireland Ltd Aparato y metodo para el suministro de medicamentos al sistema respiratorio.
US6948491B2 (en) 2001-03-20 2005-09-27 Aerogen, Inc. Convertible fluid feed system with comformable reservoir and methods
US7100600B2 (en) 2001-03-20 2006-09-05 Aerogen, Inc. Fluid filled ampoules and methods for their use in aerosolizers
JP2004513071A (ja) 2000-05-23 2004-04-30 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 肺の弾性繊維損傷に関連した呼吸器疾患の治療方法
US6338859B1 (en) 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
US6521736B2 (en) 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
IL155291A0 (en) 2000-10-16 2003-11-23 Neopharm Inc Liposomal formulation of mitoxantrone
CN1116875C (zh) 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US6497901B1 (en) 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds
EP1203614A1 (de) 2000-11-03 2002-05-08 Polymun Scientific Immunbiologische Forschung GmbH Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln
US20020160039A1 (en) 2000-12-01 2002-10-31 Biomira U.S.A., Inc. Preparation of large liposomes by infusion into peg
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
WO2002060412A2 (en) 2001-02-01 2002-08-08 Board Of Regents Stabilised polymeric aerosols for pulmonary gene delivery
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
JP2002318193A (ja) 2001-04-24 2002-10-31 Canon Inc ネブライザ及び高周波誘導結合プラズマ発光分析装置
US6554201B2 (en) 2001-05-02 2003-04-29 Aerogen, Inc. Insert molded aerosol generator and methods
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
WO2002094217A1 (en) 2001-05-18 2002-11-28 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20030060451A1 (en) 2001-05-29 2003-03-27 Rajneesh Taneja Enhancement of oral bioavailability of non-emulsified formulations of prodrug esters with lecithin
DE10126807C2 (de) 2001-06-01 2003-12-04 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
DE10126808C1 (de) 2001-06-01 2002-08-14 Pari Gmbh Inhalationsmaske
EP1269993A1 (en) 2001-06-21 2003-01-02 Applied NanoSystems B.V. Delivery of small hydrophilic molecules packaged into lipid vesicles
WO2003000236A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
WO2003015698A2 (en) 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
JP2005502653A (ja) 2001-08-20 2005-01-27 トランセーヴ・インコーポレーテッド 肺ガンの治療方法
SK1012004A3 (sk) * 2001-08-21 2005-04-01 Pfizer Products Inc. Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka
US6623723B2 (en) * 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
DE50106644D1 (de) 2001-10-18 2005-08-04 Pari Gmbh Inhalationstherapievorrichtung
DE50102690D1 (de) 2001-10-18 2004-07-29 Pari Gmbh Inhalationstherapievorrichtung
US20050119202A1 (en) 2001-10-26 2005-06-02 Roland Kreutzer Medicament to treat a fibrotic disease
US20030096774A1 (en) 2001-11-21 2003-05-22 Igor Gonda Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
EP1474198B1 (en) 2002-01-15 2015-12-30 Novartis AG System for clearing aerosols from the effective anatomic dead space
ES2603067T3 (es) 2002-01-15 2017-02-23 Novartis Ag Métodos y sistemas para hacer funcionar un generador de aerosol
EP1490027A4 (en) 2002-03-05 2010-11-10 Transave Inc METHODS OF TRAPPING BIOACTIVE AGENT IN A LIPOSOME OR LIPID COMPLEX
US20030205226A1 (en) 2002-05-02 2003-11-06 Pre Holding, Inc. Aerosol medication inhalation system
WO2003097126A2 (en) 2002-05-20 2003-11-27 Aerogen, Inc. Aerosol for medical treatment and methods
ES2354607T3 (es) 2002-06-28 2011-03-16 Protiva Biotherapeutics Inc. Procedimiento y aparato para producir liposomas.
DE60235883D1 (de) 2002-08-02 2010-05-20 Pari Pharma Gmbh Vorrichtung zur Erzeugung von Flüssigkeitströpfchen
MXPA05001312A (es) 2002-08-02 2005-08-03 Transave Inc Agregados de platino y proceso para producir los mismos.
AU2003268087A1 (en) 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery
DE10239321B3 (de) 2002-08-27 2004-04-08 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
KR100489701B1 (ko) 2002-10-09 2005-05-16 주식회사 태평양 고농도의 트리터페노이드를 함유하는 미소화 리포좀 및 그제조방법
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US20230008563A1 (en) 2002-10-29 2023-01-12 Insmed Incorporated Sustained release of antiinfectives
KR101424980B1 (ko) 2002-10-29 2014-08-01 인스메드 인코포레이티드 항감염제의 지속적인 방출
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
CN100377704C (zh) 2002-11-26 2008-04-02 吉里德科学公司 脂质体制剂
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
KR20050105455A (ko) 2003-02-11 2005-11-04 네오팜 인코포레이티드 리포좀 제제의 제조 방법
CA2516836A1 (en) 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Methods of tangential flow filtration and an apparatus therefore
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
ES2528631T3 (es) 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection
DE10320143A1 (de) 2003-05-06 2004-12-16 Pari GmbH Spezialisten für effektive Inhalation Vernebleranschlussvorrichtung für Beatmungsgeräte oder dergleichen
DE10322505B4 (de) 2003-05-19 2009-11-05 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapiemaske und -vorrichtung für Tiere
US8058493B2 (en) 2003-05-21 2011-11-15 Baker Hughes Incorporated Removing amines from hydrocarbon streams
WO2004110493A2 (en) 2003-05-30 2004-12-23 Alza Corporation Method of pulmonary administration of an agent
US8616195B2 (en) 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
WO2005019472A1 (ja) 2003-08-20 2005-03-03 Locomogene, Inc. シノビオリン活性調節作用の検出方法
GB2388581A (en) 2003-08-22 2003-11-19 Danisco Coated aqueous beads
DE10345950A1 (de) 2003-10-02 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit Ventil
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
DE10348237A1 (de) 2003-10-16 2005-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit einem Düsenvernebler
US20050214224A1 (en) 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
US7291596B2 (en) 2003-12-31 2007-11-06 Orthologic Corp. Pharmaceutical composition for thrombin peptide derivatives
US7452524B2 (en) 2004-01-27 2008-11-18 Gilead Sciences, Inc. Method for improvement of tolerance for therapeutically effective agents delivered by inhalation
US7556799B2 (en) 2004-03-30 2009-07-07 Relypsa, Inc. Ion binding polymers and uses thereof
DE102004016985B4 (de) 2004-04-07 2010-07-22 Pari Pharma Gmbh Aerosolerzeugungsvorrichtung und Inhalationsvorrichtung
JP4452799B2 (ja) 2004-07-14 2010-04-21 独立行政法人産業技術総合研究所 コアセルベートを活用したリポソームの製造方法
CA2584583A1 (en) 2004-10-28 2006-05-11 Alza Corporation Lyophilized liposome formulations and method
CA2587411A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
US8337815B2 (en) 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
DE102005006374B3 (de) 2005-02-11 2006-07-20 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung und Inhalationstherapiegerät mit einer derartigen Vorrichtung
DE102005006372B4 (de) 2005-02-11 2007-11-29 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung und Verfahren zu deren Betrieb
DE102005006375B4 (de) 2005-02-11 2007-10-11 Pari GmbH Spezialisten für effektive Inhalation Aerosolerzeugungsvorrichtung für Inhalationstherapiegeräte
US20060198940A1 (en) 2005-03-04 2006-09-07 Mcmorrow David Method of producing particles utilizing a vibrating mesh nebulizer for coating a medical appliance, a system for producing particles, and a medical appliance
JP2006263054A (ja) 2005-03-23 2006-10-05 Konica Minolta Sensing Inc 呼吸器系疾患関連解析データの取得方法、オキシメータシステム及びその動作プログラム、オキシメータ並びに酸素補給システム
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
UA94711C2 (uk) 2005-05-25 2011-06-10 Аэроджен, Инк. Вібраційна система (варіанти) та спосіб її виготовлення (варіанти), спосіб вібрування пластини (варіанти), система виробництва аерозолю та спосіб лікування пацієнта
DE102005024779B4 (de) 2005-05-31 2008-02-21 Pari GmbH Spezialisten für effektive Inhalation Atemzuggesteuerte Inhalationstherapievorrichtung
DE102005029498B4 (de) 2005-06-24 2007-08-30 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
USD638117S1 (en) 2005-06-28 2011-05-17 Pari Gmbh Inhalation therapy nebuliser
DE102005034403B3 (de) 2005-07-22 2007-02-22 Airbus Deutschland Gmbh Führungsmittel für eine Vorrichtung zur Herstellung von Faservorformlingen im TFP-Verfahren für Verbundbauteile
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
JP5162900B2 (ja) 2005-08-31 2013-03-13 東レ株式会社 ポリ乳酸系樹脂積層シートおよびその成形体
ATE439802T1 (de) 2005-09-07 2009-09-15 Koninkl Philips Electronics Nv System und verfahren zum induktiven messen der bioimpedanz eines leitfähigen gewebes
US20070065367A1 (en) * 2005-09-20 2007-03-22 Rany Condos Method of treating pulmonary disease with interferons
KR100705981B1 (ko) 2005-10-12 2007-04-10 주식회사 리제론 인간 성장호르몬을 포함하는 탈모방지 또는 발모촉진용조성물
US20070105758A1 (en) 2005-10-31 2007-05-10 May Thomas B Vancomycin formulations having reduced amount of histamine
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
DK1962805T3 (en) 2005-12-08 2016-09-26 Insmed Inc Lipid-based compositions of the anti-infective agents for the treatment of lung infections
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
DE102006006183A1 (de) 2006-02-10 2007-08-16 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung für die Anwendung bei Frühgeborenen und Kleinkindern
US7958887B2 (en) 2006-03-10 2011-06-14 Aradigm Corporation Nozzle pore configuration for intrapulmonary delivery of aerosolized formulations
DE102006012174A1 (de) 2006-03-16 2007-09-20 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapiegerätekompressor
US20080089927A1 (en) 2006-04-06 2008-04-17 Vladimir Malinin Methods for Coacervation Induced Liposomal Encapsulation and Formulations Thereof
DE102006017002B3 (de) 2006-04-11 2007-01-11 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung mit mehrfachen Düsen
USD583928S1 (en) 2006-04-27 2008-12-30 Pari Pharama Gmbh Nebulizer
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8119156B2 (en) 2006-10-24 2012-02-21 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US20080108104A1 (en) * 2006-11-02 2008-05-08 Colorado State University Research Foundation Identification of bacterial species and subspecies using lipids
EP1927373B1 (en) 2006-11-30 2012-08-22 PARI Pharma GmbH Inhalation nebulizer
US20080280986A1 (en) 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
EP1980285B1 (de) 2007-04-11 2009-11-18 PARI GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
WO2008137917A1 (en) 2007-05-07 2008-11-13 Transave, Inc. Method of treating bacterial infections with antibacterial formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) * 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
UA27298U (en) 2007-06-13 2007-10-25 Method for preventing pleural empyema after pneumonectomy
UA27804U (en) 2007-07-26 2007-11-12 Method for preventing respiratory complications after surgery in lungs and pleura
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
NZ562236A (en) * 2007-10-05 2010-04-30 Univ Otago Detection of volatile compounds as markers for Mycobacteria tuberculosis
JP5855829B2 (ja) 2007-10-23 2016-02-09 インスメッド， インコーポレイテッド リポソーム化バンコマイシン製剤
KR101303180B1 (ko) 2007-11-09 2013-09-09 삼성전자주식회사 수직채널 트랜지스터를 구비한 반도체 메모리 소자 및 그제조 방법
DE102007056462B4 (de) 2007-11-23 2011-10-27 Pari Pharma Gmbh Einwegampulle für eine Vorrichtung zur Erzeugung von Aerosolen
EP2278989B1 (en) 2008-04-08 2021-05-26 Melinta Therapeutics, Inc. Oritavancin for inhibiting and treating biofilms
DE102008022987A1 (de) 2008-05-09 2009-11-12 Pari Pharma Gmbh Vernebler für Beatmungsmaschinen und Beatmungsmaschine mit einem solchen Vernebler
JP5777519B2 (ja) 2008-10-09 2015-09-09 テクミラ ファーマシューティカルズ コーポレイション 改良されたアミノ脂質および核酸の送達方法
AU2010229721A1 (en) 2009-03-26 2011-10-06 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
ES2457442T3 (es) 2009-05-08 2014-04-25 Pari Pharma Gmbh Formulaciones farmacéuticas concentradas estabilizadoras de los mastocitos
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
SMT201700045T1 (it) 2009-07-17 2017-03-08 Nektar Therapeutics Sistemi e metodi per azionare nebulizzatori sigillati
EA023860B1 (ru) 2009-07-17 2016-07-29 Нектар Терапьютикс Герметичные распылительные системы с отрицательным сдвигом и связанные с ними способы
JP5580415B2 (ja) 2009-07-22 2014-08-27 コーニンクレッカ フィリップス エヌ ヴェ 短レスポンス時間及び高感度を持つ熱流センサ集積回路
EP2482903B1 (en) * 2009-09-29 2018-11-14 Vectura GmbH Improved method for treatment of patients with cystic fibrosis
WO2011049960A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Compositions and methods for the treatment of sinonasal disorders
US8536220B2 (en) 2010-01-26 2013-09-17 Murray Fulgham Supplement composition and method of use
WO2011108955A1 (en) 2010-03-03 2011-09-09 Universidade De Coimbra Multi -targeting system comprising a nanocarrier, nucleic acid(s) and non-nucleic acid based drug(s)
US9168225B2 (en) 2010-04-23 2015-10-27 The Board Of Trustees Of The University Of Illinois Nano-hybrid delivery system for sequential utilization of passive and active targeting
AU2011261434B2 (en) 2010-06-02 2015-11-26 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
EP2593110B1 (en) 2010-07-12 2021-01-06 Xellia Pharmaceuticals ApS Treatment of lung infections by administration of tobramycin by aerolisation
CA2809022C (en) 2010-08-20 2017-01-03 Dr. Reddy`S Laboratories, Inc. Phospholipid depot
US20120077786A1 (en) * 2010-09-27 2012-03-29 Byron David A Methods and compositions for disease treatment using inhalation
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders
EP2457609A1 (en) 2010-11-24 2012-05-30 PARI Pharma GmbH Aerosol generator
ES2913095T3 (es) 2011-01-31 2022-05-31 Avalyn Pharma Inc Compuestos de pirfenidona y análogos de piridona en aerosol y usos de los mismos
BR112013029803B1 (pt) 2011-05-19 2021-07-13 Savara, Inc Composições de vancomicina em pó seco
EP4631628A3 (en) 2011-06-08 2025-12-10 PARI Pharma GmbH Aerosol generator
DK2768958T3 (da) 2011-10-18 2019-09-16 Dicerna Pharmaceuticals Inc Kationiske aminlipider og anvendelser deraf
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
BR112014015333A2 (pt) 2011-12-22 2017-06-13 Nuvo Res Gmbh composições lipossomais de clorito ou clorato
US20130280174A1 (en) 2012-04-20 2013-10-24 The Gillette Company Personal care composition comprising metathesized unsaturated polyol esters
US9925295B2 (en) 2012-05-09 2018-03-27 Amedica Corporation Ceramic and/or glass materials and related methods
HRP20220158T1 (hr) 2012-05-21 2022-04-15 Insmed Incorporated Sustavi za liječenje plućnih infekcija
EP2882459A1 (en) * 2012-08-10 2015-06-17 University of North Texas Health Science Center Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
US20150246137A1 (en) 2012-09-27 2015-09-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
US9693958B2 (en) 2013-03-15 2017-07-04 Cureport, Inc. Methods and devices for preparation of lipid nanoparticles
US20160193148A1 (en) 2013-08-01 2016-07-07 University Of Georgia Research Foundation, Inc. Liposomal formulations for the treatment of bacterial infections
US9198359B2 (en) 2013-09-20 2015-12-01 Deere & Company Frame for a reciprocating sieve
CA2923647A1 (en) 2013-10-22 2015-04-30 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
CN107072944B (zh) 2014-04-08 2021-11-02 阿拉迪姆公司 具有抗非结核分枝杆菌活性的脂质体环丙沙星制剂
US20160120806A1 (en) 2014-04-08 2016-05-05 Aradigm Corporation Nanocrystals formed in a microenvironment
CA2943201A1 (en) 2014-04-08 2015-10-15 Aradigm Corporation Liposomes that form drug nanocrystals after freeze-thaw
ES2926985T3 (es) 2014-05-15 2022-10-31 Insmed Inc Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas
KR102235952B1 (ko) 2014-08-29 2021-04-07 이엠디 밀리포어 코포레이션 잔류물의 재순환을 이용한 싱글 패스 접선 유동 여과 시스템 및 접선 유동 여과 시스템
US10632072B2 (en) 2015-03-19 2020-04-28 University Of Connecticut Systems and methods for continuous manufacturing of liposomal drug formulations
US20180200186A1 (en) 2015-07-09 2018-07-19 Insmed Incorporated Compositions and methods for treating lung diseases and lung injury
CA3003151A1 (en) 2015-11-18 2017-05-26 Insmed Incorporated Compositions and methods for treating bacterial infections
GB201600290D0 (en) 2016-01-07 2016-02-24 Fujifilm Diosynth Biotechnologies Uk Ltd Process
US10183108B2 (en) 2016-02-04 2019-01-22 Pall Corporation Inline diafiltration with multi-channel pump
US20190029970A1 (en) 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
EP3787602A4 (en) 2018-05-02 2022-03-23 Insmed Incorporated METHODS OF MAKING LIPOSOMAL DRUG FORMULATIONS
US20200384007A1 (en) 2019-06-06 2020-12-10 Board Of Regents, The University Of Texas System Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
JP2024520789A (ja) 2021-06-09 2024-05-24 インスメッド インコーポレイテッド リポソームアミノグリコシド製剤のインビトロ放出アッセイ法

Also Published As

Publication number Publication date
AU2020204530A1 (en) 2020-07-30
US20180311267A1 (en) 2018-11-01
KR20230015496A (ko) 2023-01-31
PL3466432T3 (pl) 2021-02-08
EP4122470A1 (en) 2023-01-25
US20180185401A1 (en) 2018-07-05
CY1123411T1 (el) 2021-12-31
JP6892529B2 (ja) 2021-06-23
US12168021B2 (en) 2024-12-17
PL3142643T3 (pl) 2019-12-31
US20210228606A1 (en) 2021-07-29
US11395830B2 (en) 2022-07-26
JP2017515913A (ja) 2017-06-15
MX384843B (es) 2025-03-14
US20230037417A1 (en) 2023-02-09
SI3142643T1 (sl) 2019-11-29
US20240366643A1 (en) 2024-11-07
EP3466432A1 (en) 2019-04-10
MX2020010726A (es) 2021-07-27
US12377114B2 (en) 2025-08-05
EP3142643A1 (en) 2017-03-22
US20190160086A1 (en) 2019-05-30
US10238675B2 (en) 2019-03-26
EP3766501B1 (en) 2022-07-06
ES2820226T3 (es) 2021-04-20
JP2025122086A (ja) 2025-08-20
LT3142643T (lt) 2019-10-25
BR112016026699A8 (pt) 2021-06-29
CA2949078A1 (en) 2015-11-19
US10588918B2 (en) 2020-03-17
CN106535877A (zh) 2017-03-22
PT3142643T (pt) 2019-10-28
US20200268781A1 (en) 2020-08-27
KR20240018675A (ko) 2024-02-13
MX2016014921A (es) 2017-07-28
US20230330119A1 (en) 2023-10-19
JP6646653B2 (ja) 2020-02-14
JP7686017B2 (ja) 2025-05-30
KR20220136448A (ko) 2022-10-07
US20250057863A1 (en) 2025-02-20
US20250325574A1 (en) 2025-10-23
RS60827B1 (sr) 2020-10-30
DK3466432T3 (da) 2020-09-28
LT3466432T (lt) 2020-12-28
ME03536B (me) 2020-04-20
JP2021143187A (ja) 2021-09-24
US12168022B2 (en) 2024-12-17
JP2023033417A (ja) 2023-03-10
US11446318B2 (en) 2022-09-20
KR102447412B1 (ko) 2022-09-23
BR112016026699A2 (pt) 2017-08-15
EP3766501A1 (en) 2021-01-20
MX376012B (es) 2025-03-07
PT3466432T (pt) 2020-10-08
NZ726256A (en) 2022-11-25
AU2015258947A1 (en) 2017-01-12
CA2949078C (en) 2022-09-20
US20200345754A1 (en) 2020-11-05
EP4122470B1 (en) 2024-03-20
SI3466432T1 (sl) 2020-11-30
US20170360816A1 (en) 2017-12-21
JP2020055877A (ja) 2020-04-09
US10398719B2 (en) 2019-09-03
ES2926985T3 (es) 2022-10-31
US9895385B2 (en) 2018-02-20
AU2020204530B2 (en) 2022-06-23
US10751355B2 (en) 2020-08-25
EP4393491A3 (en) 2024-07-24
EP4393491A2 (en) 2024-07-03
AU2015258947B2 (en) 2020-04-09
US20220395524A1 (en) 2022-12-15
US12016873B2 (en) 2024-06-25
WO2015175939A1 (en) 2015-11-19
EP3142643A4 (en) 2018-01-10
US20190216834A1 (en) 2019-07-18
EP3142643B1 (en) 2019-07-10
CY1122129T1 (el) 2020-11-25
US10251900B2 (en) 2019-04-09
US20150328244A1 (en) 2015-11-19
BR112016026699B1 (pt) 2022-09-13
KR102489036B1 (ko) 2023-01-13
JP7212717B2 (ja) 2023-01-25
ES2981634T3 (es) 2024-10-09
HUE051440T2 (hu) 2021-03-01
KR102657132B1 (ko) 2024-04-12
DK3142643T3 (da) 2019-10-14
KR20170005104A (ko) 2017-01-11
EP3466432B1 (en) 2020-07-08
US10828314B2 (en) 2020-11-10
SMT202000516T1 (it) 2020-11-10
US20200009171A1 (en) 2020-01-09
ES2755941T3 (es) 2020-04-24

Similar Documents

Publication Publication Date Title
HRP20191805T1 (hr) Postupci za liječenje netuberkuloznih mikobakterijskih infekcija pluća
JP2017515913A5 (cg-RX-API-DMAC7.html)
JP2015513309A5 (cg-RX-API-DMAC7.html)
JP2016040316A5 (cg-RX-API-DMAC7.html)
JP5902628B2 (ja) 相乗的抗ウイルス組成物及びその使用
JP2019500318A (ja) 細菌感染症を治療するための組成物及び方法
BR112012004692B1 (pt) Solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano
HRP20201761T1 (hr) Prilagođeni liposomi za tretman bakterijskih infekcija
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
HRP20201515T1 (hr) Postupci za liječenje plućnih ne-tuberkuloznih mikobakterijskih infekcija
Galeva et al. WS5. 6 A challenging double-blind, placebo-controlled study of tobramycin inhalation powder in cystic fibrosis: results of the EDIT trial
ZHOU et al. Effect of nebulized corticosteroids on long-term poorly controlled asthma in elderly patients
Goldman et al. WS5. 5 A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection
Fila et al. 73 Influence of treatment with sildenafil on lung function and exercise tolerance in cystic fibrosis adults
Hayes Jr et al. Revisiting an old therapy for tuberculosis
JP2015512439A5 (cg-RX-API-DMAC7.html)
CN115607556A (zh) 预防治疗哮喘或慢阻肺或过敏性疾病等的药物
Tlatelpa Romero et al. Effect Of Inhaled Surfactant And Phosphatidylethanolamine On Bleomycin-Induced Lung Fibrosis In Mice
JP2015500841A5 (cg-RX-API-DMAC7.html)